icd 10 code for phelan mcdermid syndrome

by Carmelo Schinner 7 min read

EntryH01238 Disease
Related pathwayhsa04724 Glutamatergic synapse
GeneSHANK3 [HSA:85358] [KO:K15009]
Other DBsICD-11: LD44.NY ICD-10: Q93.5 MeSH: C536801 OMIM: 606232
ReferencePMID:11431708
7 more rows

Full Answer

What is the prognosis of Phelan McDermid syndrome (ICD-9)?

ICD-9: 758.39. ONSET AND PROGRESSION. Individuals with Phelan-McDermid syndrome generally have life-long complications associated with this disorder with no apparent life-threatening organic malformations. Individuals surviving to adulthood may not be able to function independently and may require supportive services.

What is Phelan-McDermid syndrome (PMS)?

General Discussion. Phelan-McDermid syndrome (PMS) is a rare genetic condition caused by a deletion or other structural change of the terminal end of chromosome 22 in the 22q13 region or a disease-causing mutation of the SHANK3 gene.

What tests are used to diagnose Phelan-McDermid syndrome?

Phelan-McDermid Syndrome is a rare genetic disorder that involves a deletion of 22q13 or a mutation of the SHANK3 gene. DIAGNOSTIC TESTING, PHYSICAL FINDINGS, AND ICD-9-CM/ICD-10-CM CODING Molecular genetic testing (usually chromosome microarray analysis, or CMA); or Fluorescent in situ hybridization (FISH) test analysis.

What is Phelan-McDermid syndrome (22q13 deletion syndrome)?

The 22q13.3 deletion syndrome, also known as Phelan-McDermid syndrome, is a contiguous gene disorder resulting from deletion of the distal long arm of chromosome 22.

image

What is Phelan-McDermid syndrome?

Phelan-McDermid syndrome (PMS) is a rare genetic condition that causes developmental and speech delays, behavioral problems and a weakened or no ability to feel pain or sweat. Phelan-McDermid syndrome is a congenital condition (condition that is present at birth) that can affect people of all genders.

Is Phelan-McDermid syndrome a neurological disorder?

Phelan-McDermid syndrome, also called 22q13 deletion syndrome, is a genetic disorder caused by deletion of part of chromosome 22 or a defect in a gene called SHANK3. The disorder can cause a wide range of symptoms varying in severity.

When is Phelan-McDermid syndrome diagnosed?

Because the genetic changes vary, Phelan-McDermid syndrome (PMS) symptoms vary too, and can cause a wide range of medical, intellectual, and behavioral challenges. People who have PMS often show symptoms in very early childhood, sometimes at birth and within the first six months of life.

Is Phelan-McDermid a terminal?

According to the Phelan-McDermid Syndrome Registry, of 232 individuals with microarray results, 181 (79%) have terminal or interstitial deletions, 41 (18%) have unbalanced translocations or other structural abnormalities leading to deletion, and 7 (3%) have SHANK3 pathogenic variants. 7.

Is Phelan-McDermid syndrome a form of autism?

About 84 percent of people with Phelan-McDermid syndrome have autism2. The syndrome can also include developmental delay and unusual physical features.

Why is it called Phelan-McDermid?

In 2002, a group of parents suggested that the official name of the syndrome should be called Phelan-McDermid Syndrome, after Dr. Katy Phelan and researcher Heather McDermid from the University of Alberta. In 2003, 22q13 deletion syndrome officially became known as Phelan-McDermid Syndrome.

How many people in the world have Phelan-McDermid?

There have since been over 500 identified cases worldwide. The deletion occurs in equal frequency in males and females. It is now often referred to as Phelan-McDermid syndrome, named after the people who first described and characterised the disorder: Drs Katy Phelan and Heather McDermid.

How do you test for Phelan-McDermid syndrome?

Tests Used For DiagnosisThese tests are most commonly used to diagnose Phelan-McDermid syndrome (PMS):Chromosomal Microarray Analysis (CMA) is a genetic test that is most commonly used to diagnose PMS and involves only providing a small amount of blood.More items...

Can Phelan-McDermid be diagnosed before birth?

Generally, Phelan-McDermid syndrome will not be diagnosed prenatally. Testing usually is initiated as a result of trying to identify the cause of hypotonia or global developmental delay. Genetic testing may be performed by a variety of methods. The most common testing method is chromosomal microarray analysis (CMA).

What is Soto's disease?

Definition. Sotos syndrome (cerebral gigantism) is a rare genetic disorder caused by mutation in the NSD1 gene on chromosome 5. It is characterized by excessive physical growth during the first few years of life.Sotos Syndrome | National Institute of Neurological Disorders and Strokehttps://www.ninds.nih.gov › health-information › sotos-sy...https://www.ninds.nih.gov › health-information › sotos-sy...

What is the 22nd chromosome responsible for?

Sequencing and mapping efforts have already revealed that chromosome 22 is implicated in the workings of the immune system, congenital heart disease, schizophrenia, mental retardation, birth defects, and several cancers including leukemia.NIH News Release: Human Chromosome 22: First to be Decodedhttps://web.ornl.gov › Human_Genome › project › chr22https://web.ornl.gov › Human_Genome › project › chr22

What is the 8th chromosome responsible for?

Chromosome 8 is one of the 23 pairs of chromosomes in humans. People normally have two copies of this chromosome. Chromosome 8 spans about 145 million base pairs (the building material of DNA) and represents between 4.5 and 5.0% of the total DNA in cells....Chromosome 8GenBankCM000670 (FASTA)19 more rowsChromosome 8 - Wikipediahttps://en.wikipedia.org › wiki › Chromosome_8https://en.wikipedia.org › wiki › Chromosome_8

What is the ICd 10 code for deletion of chromosomes?

Other deletions of part of a chromosome 1 Q93.5 should not be used for reimbursement purposes as there are multiple codes below it that contain a greater level of detail. 2 The 2021 edition of ICD-10-CM Q93.5 became effective on October 1, 2020. 3 This is the American ICD-10-CM version of Q93.5 - other international versions of ICD-10 Q93.5 may differ.

What are the disorders of the long arm of chromosome 15?

A genetic syndrome characterized by mental retardation, speech impairment, microcephaly, ataxia, and seizures. The majority of cases result from deletions on the long arm of chromosome 15.

What is the ICD code for chromosome replacement?

Q93.2 is a billable ICD code used to specify a diagnosis of chromosome replaced with ring, dicentric or isochromosome. A 'billable code' is detailed enough to be used to specify a medical diagnosis.

What is PMS mutation?

The Developmental Synaptopathies Consortium defines PMS as being caused by SHANK3 mutations, a definition that excludes terminal deletions.

What is 22q13 deletion syndrome?

22q13 deletion syndrome (spoken as twenty-two q one three) is a genetic disorder caused by deletions or rearrangements on the q terminal end (long arm) of chromosome 22. Any abnormal genetic variation in the q13 region that presents with significant manifestations (phenotype) typical of a terminal deletion should be diagnosed as 22q13 deletion syndrome. 22q13 deletion syndrome is often placed in the more general category of Phelan-McDermid Syndrome (abbreviated PMS), which includes some mutations and microdeletions. The PMS name is less precise, since there is disagreement among researchers as to which variants belong in the PMS category. The Developmental Synaptopathies Consortium defines PMS as being caused by SHANK3 mutations, a definition that excludes terminal deletions. This latter definition of PMS is incompatible with the defintion of 22q13 deletion syndrome by those who first described 22q13 deletion syndrome.

What is billable code?

Billable codes are sufficient justification for admission to an acute care hospital when used a principal diagnosis. The Center for Medicare & Medicaid Services (CMS) requires medical coders to indicate whether or not a condition was present at the time of admission, in order to properly assign MS-DRG codes.

What is the Phelan-McDermid Syndrome Foundation?

The Phelan-McDermid Syndrome Foundation’s (PMSF) goal is to find effective clinical therapies and, eventually, a cure. In 2010, the PMSF launched a strategic plan for science to accelerate PMS research.

What is PMS in children?

As children grow, additional symptoms develop. People with PMS typically have moderate to severe developmental and intellectual impairment, most do not acquire functional language, and about 75% have been diagnosed with an autism spectrum disorder.

What test is done to determine if a child's deletion is de novo?

Parents should undergo metaphase FISH and/or karyotype testing to determine if the child’s deletion is de novo (spontaneous) or if it resulted from a parental chromosomal rearrangement, such as a balanced translocation or inversion, or if one of the parents themselves has the same deletion.

What is the genetic mutation of chromosome 22?

Phelan-McDermid syndrome (PMS) is a rare genetic condition caused by a deletion or other structural change of the terminal end of chromosome 22 in the 22 q13 region or a disease-causing mutation of the SHANK3 gene. Although the range and severity of symptoms may vary, PMS is generally thought to be characterized by neonatal hypotonia (low muscle tone in the newborn), normal growth, absent to severely delayed speech, moderate to profound developmental delay, and minor dysmorphic features.

What is PMS mutation?

The Developmental Synaptopathies Consortium defines PMS as being caused by SHANK3 mutations, a definition that excludes terminal deletions.

What is 22q13 deletion syndrome?

22q13 deletion syndrome (spoken as twenty-two q one three) is a genetic disorder caused by deletions or rearrangements on the q terminal end (long arm) of chromosome 22. Any abnormal genetic variation in the q13 region that presents with significant manifestations (phenotype) typical of a terminal deletion should be diagnosed as 22q13 deletion syndrome. 22q13 deletion syndrome is often placed in the more general category of Phelan-McDermid Syndrome (abbreviated PMS), which includes some mutations and microdeletions. The PMS name is less precise, since there is disagreement among researchers as to which variants belong in the PMS category. The Developmental Synaptopathies Consortium defines PMS as being caused by SHANK3 mutations, a definition that excludes terminal deletions. This latter definition of PMS is incompatible with the defintion of 22q13 deletion syndrome by those who first described 22q13 deletion syndrome.

What is billable code?

Billable codes are sufficient justification for admission to an acute care hospital when used a principal diagnosis. The Center for Medicare & Medicaid Services (CMS) requires medical coders to indicate whether or not a condition was present at the time of admission, in order to properly assign MS-DRG codes.

Signs and symptoms

Affected individuals present with a broad array of medical and behavioral manifestations (tables 1 and 2). Patients are consistently characterized by global developmental delay, intellectual disability, speech abnormalities, ASD -like behaviors, hypotonia and mild dysmorphic features.

Cause

Various deletions affect the terminal region of the long arm of chromosome 22 (the paternal chromosome in 75% of cases ), from 22q13.3 to 22qter. Although the deletion is most typically a result of a de novo mutation, there is an inherited form resulting from familial chromosomal translocations involving the 22 chromosome.

Epidemiology

The true prevalence of PMS has not been determined. More than 1,200 people have been identified worldwide according to the Phelan–McDermid Syndrome Foundation. However, it is believed to be underdiagnosed due to inadequate genetic testing and lack of specific clinical features. It is known to occur with equal frequency in males and females.

History

The first case of PMS was described in 1985 by Watt et al., who described a 14-year-old boy with severe intellectual disability, mild dysmorphic features and absent speech, which was associated with terminal loss of the distal arm of chromosome 22. In 1988, Phelan et al.

image

Prevention

Signs and symptoms

  • Most infants with PMS exhibit normal growth before birth (intrauterine growth) with normal growth after birth (postnatally). The first physical sign associated with PMS is neonatal hypotonia (low muscle tone) which may be accompanied by feeding difficulties, weak cry, and poor head control. Children also experience significant delay in reaching early developmental milestones, s…
See more on rarediseases.org

Characteristics

  • The facial features associated with PMS include long head shape (dolicocephaly), large/prominent ears, full brow, deep set eyes, long eyelashes, full or puffy eyelids, droopy eyelids (ptosis), flat midface, full or puffy cheeks, wide nasal bridge, bulbous nose, and pointed chin. Other features include relatively large hands and underdeveloped (dysplastic) toenails. Behavior …
See more on rarediseases.org

Prognosis

  • Although significant information is not available on older individuals with PMS, current data suggest that lymphedema (accumulation of fluid in the arms and legs) and cellulitis (inflammation of subcutaneous tissue due to infection) may develop during the teenage and early adult years.
See more on rarediseases.org

Cause

  • PMS is caused by the deletion or disruption of the segment of the long arm (q) of chromosome 22 that is identified as 22q13. Chromosomes are found in the nucleus of all body cells. They carry the genetic information for the growth and development of each individual. Pairs of human chromosomes include the autosomes, numbered from 1 to 22, and the se...
See more on rarediseases.org

Nomenclature

  • Because the deletion of chromosome 22 typically occurs on the distal portion of the long arm of the chromosome that is away from the center (distal), it is often referred to as a terminal deletion. In this sense, terminal refers to the end of the chromosome. It is important that families and healthcare providers understand that in this context terminal refers to the distal portion of the ch…
See more on rarediseases.org

Epidemiology

  • PMS was initially described in the medical literature in 1985. Since that time, additional cases have been reported in the literature, with more than 1500 members in the Phelan-McDermid Syndrome Foundation membership. Males and females are equally likely to be affected. Based on limited statistical analysis, the occurrence rate has been estimated to fall in the range of 2.5-10 …
See more on rarediseases.org

Diagnosis

  • PMS should be considered in individuals suspected of having Angelman syndrome and Rett syndrome but without the characteristic chromosomal or molecular defects associated with these syndromes. Several individuals previously classified as atypical Angelman or atypical Rett syndrome have been subsequently shown to have deletion or mutation of 22q13. Features that t…
See more on rarediseases.org

Research

  • Whole exome sequencing (WES): If chromosomal microarray analysis (CMA) has been done, but a pathogenic deletion is not identified, the next step is WES. WES detects genetic spelling errors, called variants, in genetic sequence. Some variants are benign (do not cause disease). Some variants have uncertain effects (variants of unknown significance). Other variants are known to …
See more on rarediseases.org

Clinical significance

  • Pathogenic mutations of the SHANK3 gene are associated with PMS. If a likely pathogenic variant of SHANK3 is detected, the parents should also undergo WES to determine if one of the parents carries the same variant. If the variant is present in a healthy parent, it is unlikely to be pathogenic. Indeed, pathogenic mutations in SHANK3 are de novo in the vast majority of people with PMS (t…
See more on rarediseases.org

Treatment

  • Treatment The treatment for PMS addresses the specific symptoms of each individual and typically requires the coordinated efforts of a team of specialists that may include several of the following. pediatricians, neurologists, nephrologists, gastroenterologists, immunologists, orthopedists, physical or occupational therapists, and speech/language pathologists. Cardiac ab…
See more on rarediseases.org

Achievements

  • The growth within both the PMSF and research communities has been astronomical in the past few years. PMSF has contributed to the growth through grants and fellowships, advocacy, engaging families in research initiatives, and establishing relationships with researchers and funders worldwide.
See more on rarediseases.org

Goals

  • The goal of current research is to provide families and healthcare professionals with a better understanding of the natural history of this disorder. The information obtained through various research projects is shared with the parents through quarterly newsletters, personal communications, and through scientific presentations at biennial meetings of the PMSF. Inform…
See more on rarediseases.org

Participants

  • For information on potential participation in these studies or for more general information concerning research, family support or advocacy, physicians and parents may contact:
See more on rarediseases.org

Resources

  • [email protected] Information on current clinical trials is posted on the Internet at www.clinicaltrials.gov. All studies receiving U.S. government funding, and some supported by private industry, are posted on this government website.
See more on rarediseases.org